CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...